Applied StemCell and RoosterBio collaborate to advance scalable iPSC-based bioprocessing
Applied StemCell (ASC) is excited to announce a strategic partnership with RoosterBio focused on developing and commercializing scalable iPSC-based bioprocess solutions for advanced therapy developers.
The collaboration will pair our GMP-compatible induced pluripotent stem cell (iPSC) technology with RoosterBio’s engineered media, reagents, and scalable bioprocess systems, combining our expertise in genome engineering and iPSC derivation with RoosterBio’s bioprocessing knowledge and manufacturing solutions.
Together, we aim to shorten process development cycles, improve consistency, and support a smoother transition from early research toward scalable clinical manufacturing, strengthening the broader advanced therapy ecosystem and the growing global demand for high-quality iPSC-based products.
“By pairing our iPSC technology and genome engineering expertise with RoosterBio’s purpose-built media and bioprocess systems, we see an opportunity to give developers an integrated solution that accelerates the path from research to scalable clinical manufacturing.”
– Dolores Baksh, Ph.D.
CEO of Applied StemCell
Key areas of collaboration
- Engineered iPSC platforms
- Scalable bioprocess media and reagents
- GMP-compatible manufacturing workflows
- Advanced therapy process development
- Cellular starting materials and product quality
- Research-to-clinic translation
